<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01742364</url>
  </required_header>
  <id_info>
    <org_study_id>HS 645</org_study_id>
    <nct_id>NCT01742364</nct_id>
  </id_info>
  <brief_title>Comparative Study of Bacille Calmette Guerin (BCG) Delivery Via Disposable Syringe Jet Injector and Needle &amp; Syringe</brief_title>
  <official_title>A Randomized Clinical Trial in Adults and Newborns to Compare the Safety, Reactogenicity and Immunogenicity of BCG Administration Via a Disposable Syringe Jet Injector (DSJI) to BCG Administration Via Syringe and Needle</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PATH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>World Health Organization</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Cape Town</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>PATH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to test the hypothesis that BCG administration via jet injector will
      produce a comparable immune response and that there will be no significant differences in
      safety or reactogenicity between BCG administration via jet injector and needle and syringe.

      The primary objectives of this study are to...

        1. Compare the safety and reactogenicity of BCG administered intradermally by a jet
           injector device in adults and infants, to BCG administered intradermally by needle and
           syringe;

        2. Compare the specific T cell immunity in neonates vaccinated with BCG via the jet
           injector device to infants vaccinated with BCG via needle and syringe.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, controlled, partially blinded clinical trial in 2 stages (adult stage, infant
      stage) will be applied at a single site.

      The first stage will include thirty (30) adult participants. The Data Safety Monitoring Board
      (DSMB) will evaluate the reactogenicity and safety data for all 30 adults up to day 28 after
      vaccination. Pending a favourable safety review by the DSMB, the second stage in sixty-six
      (66) newborn participants will commence. Potential adult and infant participants will be
      screened prior to enrolment to apply inclusion and exclusion criteria.Note that as the adult
      stage was a pilot, only results of the infant study are presented here.

      In each of the stages half of the study population (15 adults, 33 neonates) will receive BCG
      via conventional syringe and needle (standard of care administration technique), and half (15
      adults, 33 neonates) will receive BCG via jet injector (investigational administration
      technique). A single and standard volume and dose of BCG will be administered per the package
      insert. Neonates will receive their BCG shortly after birth.

      The occurrence of injection site reactogenicity events and systemic adverse events will be
      compared between study groups in both adults and neonates. In the neonate stage, BCG and M.tb
      specific immunogenicity will also be compared between study groups.

      For the adult stage the vaccinator and participant will be unblinded to study arm allocation.
      For the infant stage, the vaccinator will be unblinded but the participant caregiver will be
      blinded. For both the adult and infant stages the follow-up team will be blinded to study arm
      allocation. The laboratory will be blinded to study arm allocation for the infant stage
      immunogenicity assays.

      The trial will be conducted at the field site of the South African Tuberculosis Vaccine
      Initiative (SATVI) in the Cape Winelands East district of the Western Cape of South Africa.
      Recruitment and vaccination of neonates will take place at 1 or more of the state public
      healthcare antenatal clinics and birthing units in the area. Recruitment and vaccination of
      adults, as well as follow-up of adults and the neonates/infants will take place on the SATVI
      field site premises, or on the premises of the public healthcare clinic. All study
      procedures, including vaccination, will be performed by SATVI study staff.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Injection Site Adverse Events (Following Injection)</measure>
    <time_frame>14 weeks</time_frame>
    <description>Injection site adverse events including redness, swelling, induration, tenderness, ulceration, fluctuation , drainage, laceration, bruising, and scarring will be monitored for up to fourteen weeks following vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Systemic Adverse Events</measure>
    <time_frame>14 weeks</time_frame>
    <description>Systemic adverse events, solicited and unsolicited, including symptoms of lethargy, disrupted feeding patterns, fever, lymphadenopathy, rash, or any other physical abnormalities will be monitored for up to fourteen weeks following vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Short Term Whole Blood Intracellular Cytokine Staining Assay for BCG-specific CD4 (Cluster of Differentiation 4) T-cells</measure>
    <time_frame>10 weeks post-vaccination</time_frame>
    <description>BCG-specific immunogenicity was tested in infants only, since they are the target study population and BCG immunogenicity in adults is known to be different from that in infants.
Utilizing a whole-blood intracellular cytokine staining (ICS) assay, we analyzed cytokine co-expression patterns by BCG-specific CD4 and CD8 T-cells. Briefly, 0.5 ml heparinized whole blood was incubated for 12 hours with BCG, no antigen or phytohemagglutinin (PHA) in the presence of anti-CD28 and anti-CD49d, with the last 5 hours including Brefeldin A prior to treating with BD FACS™ Lysing Solution and cryopreservation. Cells were batch-thawed, permeabilized with BD Perm/Wash™ buffer, and stained with fluorescent antibodies. At least 120,000 CD3+CD4+ T-cells were acquired for the no-antigen and BCG samples on a BD™ LSR II flow cytometer.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Short Term Whole Blood Intracellular Cytokine Staining Assay for BCG-specific CD4 T-cells</measure>
    <time_frame>14 weeks post-vaccination</time_frame>
    <description>BCG-specific immunogenicity was tested in infants only, since they are the target study population and BCG immunogenicity in adults is known to be different from that in infants.
Utilizing a whole-blood intracellular cytokine staining (ICS) assay, we analyzed cytokine co-expression patterns by BCG-specific CD4 and CD8 T-cells. Briefly, 0.5 ml heparinized whole blood was incubated for 12 hours with BCG, no antigen or phytohemagglutinin (PHA) in the presence of anti-CD28 and anti-CD49d, with the last 5 hours including Brefeldin A prior to treating with BD FACS™ Lysing Solution and cryopreservation. Cells were batch-thawed, permeabilized with BD Perm/Wash™ buffer, and stained with fluorescent antibodies. At least 120,000 CD3+CD4+ T-cells were acquired for the no-antigen and BCG samples on a BD™ LSR II flow cytometer.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Diameter of Skin Bleb</measure>
    <time_frame>Immediately post-vaccination</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Fluid Leakage on Skin at Injection Site</measure>
    <time_frame>Immediately post-vaccination</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">96</enrollment>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>Bioject Intradermal (ID) Pen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intradermal administration of BCG vaccine via the Bioject ID Pen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Needle and syringe</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intradermal administration of BCG vaccine via needle and syringe.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Bioject ID Pen</intervention_name>
    <description>Participants in this arm will receive a standard dose of BCG via the Bioject ID needle-free jet injector device (investigational administration technique).</description>
    <arm_group_label>Bioject Intradermal (ID) Pen</arm_group_label>
    <other_name>Disposable Syringe Jet Injector</other_name>
    <other_name>DSJI</other_name>
    <other_name>Jet Injector</other_name>
    <other_name>ID Pen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Needle and syringe</intervention_name>
    <description>Participants in this arm will receive a standard dose of BCG via syringe and needle by the Mantoux technique (standard of care administration technique).</description>
    <arm_group_label>Needle and syringe</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Adult stage

          -  Inclusion criteria:

               1. Male or female, age 18 to 50 years.

               2. Written informed consent, including permission for access to medical records and
                  an HIV test.

               3. Available for study follow up and display a willingness and capacity to comply to
                  study procedures.

               4. In good general health, as assessed by medical history and a focused physical
                  examination.

               5. HIV test (rapid test, ELISA [enzyme-linked immunosorbent assay], or PCR
                  [polymerase chain reaction]) negative.

               6. Quantiferon®-TB Gold (Cellestis) test for latent TB infection negative within 2
                  weeks of enrolment.

               7. BCG vaccination at birth as confirmed by history or the presence of a BCG scar.

               8. In the case of female participants, a negative urine or serum pregnancy test at
                  enrolment, and not pregnant or lactating. Evidence of contraception is not
                  required since BCG is not contra-indicated in pregnancy.

          -  Exclusion criteria:

               1. A history or evidence of a significant or chronic medical condition or disease.

               2. Skin condition, bruising or birth mark at the intended injection site.

               3. History of previous active tuberculosis (TB) disease or current active TB
                  disease.

               4. History of a household contact with active TB disease who has received less than
                  2 months treatment.

        Neonate Stage

          -  Inclusion criteria:

               1. Male or female neonates within 48 hours of birth.

               2. Written informed consent, including permission to access medical records and
                  results of antenatal HIV tests.

               3. Infant participants and their caregivers available for study follow-up and
                  display the willingness and capacity to comply with study procedures.

               4. Neonates must be in good general health as assessed by medical history during
                  pregnancy and delivery, and focused physical examination.

               5. Birth weight more than or equal to 2500 grams.

               6. Apgar score at 5 minutes more than or equal to 7.

               7. A maternal HIV test result (rapid test, ELISA or PCR) taken during pregnancy must
                  be available, documented and negative.

          -  Exclusion criteria:

               1. Participant must not have received BCG vaccination prior to enrolment.

               2. Significant antenatal or intrapartum complications that may affect the health of
                  the neonate.

               3. Skin condition, bruising or birth mark at the intended injection site.

               4. Maternal HIV test (rapid test, ELISA or PCR) not performed antenatally, HIV test
                  results not available, or HIV test result known positive.

               5. Maternal history of current active TB, or other household contact with known
                  active TB disease who has received less than 2 months of treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hennie Geldenhuys</last_name>
    <role>Principal Investigator</role>
    <affiliation>South African Tuberculosis Vaccine Initiative</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SATVI, University of Cape Town</name>
      <address>
        <city>Cape Town</city>
        <zip>7925</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2012</study_first_submitted>
  <study_first_submitted_qc>December 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2012</study_first_posted>
  <results_first_submitted>April 6, 2016</results_first_submitted>
  <results_first_submitted_qc>December 15, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 8, 2017</results_first_posted>
  <last_update_submitted>December 15, 2016</last_update_submitted>
  <last_update_submitted_qc>December 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>disposable syringe jet injector (DSJI)</keyword>
  <keyword>DSJI</keyword>
  <keyword>BCG</keyword>
  <keyword>tuberculosis</keyword>
  <keyword>intradermal delivery</keyword>
  <keyword>South Africa</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Infants: 131 consents obtained; 50 screening failures, no participation refusals, and 66 enrolled at birth. 15 infants were consented, screened, and eligible for participation but were not enrolled because the enrollment target had been reached.
Adults: 95 consents obtained; 63 screening failures, 2 participation refusals, and 30 enrolled.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>INFANTS: Bioject Intradermal (ID) Pen</title>
          <description>Intradermal administration of BCG vaccine via the Bioject ID Pen.
Bioject ID Pen</description>
        </group>
        <group group_id="P2">
          <title>INFANTS: Needle and Syringe</title>
          <description>Intradermal administration of BCG vaccine via needle and syringe.
Needle and syringe</description>
        </group>
        <group group_id="P3">
          <title>ADULTS: Bioject Intradermal (ID) Pen</title>
          <description>Intradermal administration of BCG vaccine via the Bioject ID Pen.
Bioject ID Pen</description>
        </group>
        <group group_id="P4">
          <title>ADULTS: Needle and Syringe</title>
          <description>Intradermal administration of BCG vaccine via needle and syringe.
Needle and syringe</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="33"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="33"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Infants (n=66) and Adults (n=30)</population>
      <group_list>
        <group group_id="B1">
          <title>INFANTS: Bioject Intradermal (ID) Pen</title>
          <description>Intradermal administration of BCG vaccine via the Bioject ID Pen.
Bioject ID Pen</description>
        </group>
        <group group_id="B2">
          <title>INFANTS: Needle and Syringe</title>
          <description>Intradermal administration of BCG vaccine via needle and syringe.
Needle and syringe</description>
        </group>
        <group group_id="B3">
          <title>ADULTS: Bioject Intradermal (ID) Pen</title>
          <description>Intradermal administration of BCG vaccine via the Bioject ID Pen.
Bioject ID Pen</description>
        </group>
        <group group_id="B4">
          <title>ADULTS: Needle and Syringe</title>
          <description>Intradermal administration of BCG vaccine via needle and syringe.
Needle and syringe</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="33"/>
            <count group_id="B2" value="33"/>
            <count group_id="B3" value="15"/>
            <count group_id="B4" value="15"/>
            <count group_id="B5" value="96"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="66"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="57"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Injection Site Adverse Events (Following Injection)</title>
        <description>Injection site adverse events including redness, swelling, induration, tenderness, ulceration, fluctuation , drainage, laceration, bruising, and scarring will be monitored for up to fourteen weeks following vaccination.</description>
        <time_frame>14 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>INFANTS: Bioject Intradermal (ID) Pen</title>
            <description>Intradermal administration of BCG vaccine via the Bioject ID Pen.
Bioject ID Pen</description>
          </group>
          <group group_id="O2">
            <title>INFANTS: Needle and Syringe</title>
            <description>Intradermal administration of BCG vaccine via needle and syringe.
Needle and syringe</description>
          </group>
          <group group_id="O3">
            <title>ADULTS: Bioject Intradermal (ID) Pen</title>
            <description>Intradermal administration of BCG vaccine via the Bioject ID Pen.
Bioject ID Pen</description>
          </group>
          <group group_id="O4">
            <title>ADULTS: Needle and Syringe</title>
            <description>Intradermal administration of BCG vaccine via needle and syringe.
Needle and syringe</description>
          </group>
        </group_list>
        <measure>
          <title>Injection Site Adverse Events (Following Injection)</title>
          <description>Injection site adverse events including redness, swelling, induration, tenderness, ulceration, fluctuation , drainage, laceration, bruising, and scarring will be monitored for up to fourteen weeks following vaccination.</description>
          <units>Adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="138"/>
                    <measurement group_id="O2" value="141"/>
                    <measurement group_id="O3" value="126"/>
                    <measurement group_id="O4" value="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of all adverse events (both injection site and systemic AEs).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.475</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison of all adverse events (both injection site and systemic AEs).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.187</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Systemic Adverse Events</title>
        <description>Systemic adverse events, solicited and unsolicited, including symptoms of lethargy, disrupted feeding patterns, fever, lymphadenopathy, rash, or any other physical abnormalities will be monitored for up to fourteen weeks following vaccination.</description>
        <time_frame>14 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bioject Intradermal (ID) Pen</title>
            <description>Intradermal administration of BCG vaccine via the Bioject ID Pen.
Bioject ID Pen</description>
          </group>
          <group group_id="O2">
            <title>INFANTS: Needle and Syringe</title>
            <description>Intradermal administration of BCG vaccine via needle and syringe.
Needle and syringe</description>
          </group>
          <group group_id="O3">
            <title>ADULTS: Bioject Intradermal (ID) Pen</title>
            <description>Intradermal administration of BCG vaccine via the Bioject ID Pen.
Bioject ID Pen</description>
          </group>
          <group group_id="O4">
            <title>ADULTS: Needle and Syringe</title>
            <description>Intradermal administration of BCG vaccine via needle and syringe.
Needle and syringe</description>
          </group>
        </group_list>
        <measure>
          <title>Systemic Adverse Events</title>
          <description>Systemic adverse events, solicited and unsolicited, including symptoms of lethargy, disrupted feeding patterns, fever, lymphadenopathy, rash, or any other physical abnormalities will be monitored for up to fourteen weeks following vaccination.</description>
          <units>Adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Short Term Whole Blood Intracellular Cytokine Staining Assay for BCG-specific CD4 (Cluster of Differentiation 4) T-cells</title>
        <description>BCG-specific immunogenicity was tested in infants only, since they are the target study population and BCG immunogenicity in adults is known to be different from that in infants.
Utilizing a whole-blood intracellular cytokine staining (ICS) assay, we analyzed cytokine co-expression patterns by BCG-specific CD4 and CD8 T-cells. Briefly, 0.5 ml heparinized whole blood was incubated for 12 hours with BCG, no antigen or phytohemagglutinin (PHA) in the presence of anti-CD28 and anti-CD49d, with the last 5 hours including Brefeldin A prior to treating with BD FACS™ Lysing Solution and cryopreservation. Cells were batch-thawed, permeabilized with BD Perm/Wash™ buffer, and stained with fluorescent antibodies. At least 120,000 CD3+CD4+ T-cells were acquired for the no-antigen and BCG samples on a BD™ LSR II flow cytometer.</description>
        <time_frame>10 weeks post-vaccination</time_frame>
        <population>Due to failed phlebotomy on 5 infants, results were not available for 2 participants in the Bioject ID Pen arm and for 3 participants in the Needle and syringe arm.
Immunogenicity was not measured for adults in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>INFANTS: Bioject Intradermal (ID) Pen</title>
            <description>Intradermal administration of BCG vaccine via the Bioject ID Pen.
Bioject ID Pen</description>
          </group>
          <group group_id="O2">
            <title>INFANTS: Needle and Syringe</title>
            <description>Intradermal administration of BCG vaccine via needle and syringe.
Needle and syringe</description>
          </group>
        </group_list>
        <measure>
          <title>Short Term Whole Blood Intracellular Cytokine Staining Assay for BCG-specific CD4 (Cluster of Differentiation 4) T-cells</title>
          <description>BCG-specific immunogenicity was tested in infants only, since they are the target study population and BCG immunogenicity in adults is known to be different from that in infants.
Utilizing a whole-blood intracellular cytokine staining (ICS) assay, we analyzed cytokine co-expression patterns by BCG-specific CD4 and CD8 T-cells. Briefly, 0.5 ml heparinized whole blood was incubated for 12 hours with BCG, no antigen or phytohemagglutinin (PHA) in the presence of anti-CD28 and anti-CD49d, with the last 5 hours including Brefeldin A prior to treating with BD FACS™ Lysing Solution and cryopreservation. Cells were batch-thawed, permeabilized with BD Perm/Wash™ buffer, and stained with fluorescent antibodies. At least 120,000 CD3+CD4+ T-cells were acquired for the no-antigen and BCG samples on a BD™ LSR II flow cytometer.</description>
          <population>Due to failed phlebotomy on 5 infants, results were not available for 2 participants in the Bioject ID Pen arm and for 3 participants in the Needle and syringe arm.
Immunogenicity was not measured for adults in the study.</population>
          <units>percentage responding to cytokines</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.664" lower_limit="0.410" upper_limit="1.160"/>
                    <measurement group_id="O2" value="0.485" lower_limit="0.308" upper_limit="0.842"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.205</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Short Term Whole Blood Intracellular Cytokine Staining Assay for BCG-specific CD4 T-cells</title>
        <description>BCG-specific immunogenicity was tested in infants only, since they are the target study population and BCG immunogenicity in adults is known to be different from that in infants.
Utilizing a whole-blood intracellular cytokine staining (ICS) assay, we analyzed cytokine co-expression patterns by BCG-specific CD4 and CD8 T-cells. Briefly, 0.5 ml heparinized whole blood was incubated for 12 hours with BCG, no antigen or phytohemagglutinin (PHA) in the presence of anti-CD28 and anti-CD49d, with the last 5 hours including Brefeldin A prior to treating with BD FACS™ Lysing Solution and cryopreservation. Cells were batch-thawed, permeabilized with BD Perm/Wash™ buffer, and stained with fluorescent antibodies. At least 120,000 CD3+CD4+ T-cells were acquired for the no-antigen and BCG samples on a BD™ LSR II flow cytometer.</description>
        <time_frame>14 weeks post-vaccination</time_frame>
        <population>Due to failed phlebotomy on 5 infants, results were not available for 2 participants in the Bioject ID Pen arm and for 3 participants in the Needle and syringe arm.
Immunogenicity was not measured for adults in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>INFANTS: Bioject Intradermal (ID) Pen</title>
            <description>Intradermal administration of BCG vaccine via the Bioject ID Pen.
Bioject ID Pen</description>
          </group>
          <group group_id="O2">
            <title>INFANTS: Needle and Syringe</title>
            <description>Intradermal administration of BCG vaccine via needle and syringe.
Needle and syringe</description>
          </group>
        </group_list>
        <measure>
          <title>Short Term Whole Blood Intracellular Cytokine Staining Assay for BCG-specific CD4 T-cells</title>
          <description>BCG-specific immunogenicity was tested in infants only, since they are the target study population and BCG immunogenicity in adults is known to be different from that in infants.
Utilizing a whole-blood intracellular cytokine staining (ICS) assay, we analyzed cytokine co-expression patterns by BCG-specific CD4 and CD8 T-cells. Briefly, 0.5 ml heparinized whole blood was incubated for 12 hours with BCG, no antigen or phytohemagglutinin (PHA) in the presence of anti-CD28 and anti-CD49d, with the last 5 hours including Brefeldin A prior to treating with BD FACS™ Lysing Solution and cryopreservation. Cells were batch-thawed, permeabilized with BD Perm/Wash™ buffer, and stained with fluorescent antibodies. At least 120,000 CD3+CD4+ T-cells were acquired for the no-antigen and BCG samples on a BD™ LSR II flow cytometer.</description>
          <population>Due to failed phlebotomy on 5 infants, results were not available for 2 participants in the Bioject ID Pen arm and for 3 participants in the Needle and syringe arm.
Immunogenicity was not measured for adults in the study.</population>
          <units>percentage responding to cytokines</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.386" lower_limit="0.242" upper_limit="0.637"/>
                    <measurement group_id="O2" value="0.325" lower_limit="0.227" upper_limit="0.427"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.325</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Diameter of Skin Bleb</title>
        <time_frame>Immediately post-vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>INFANTS: Bioject Intradermal (ID) Pen</title>
            <description>Intradermal administration of BCG vaccine via the Bioject ID Pen.
Bioject ID Pen</description>
          </group>
          <group group_id="O2">
            <title>INFANTS: Needle and Syringe</title>
            <description>Intradermal administration of BCG vaccine via needle and syringe.
Needle and syringe</description>
          </group>
          <group group_id="O3">
            <title>ADULTS: Bioject Intradermal (ID) Pen</title>
            <description>Intradermal administration of BCG vaccine via the Bioject ID Pen.
Bioject ID Pen</description>
          </group>
          <group group_id="O4">
            <title>ADULTS: Needle and Syringe</title>
            <description>Intradermal administration of BCG vaccine via needle and syringe.
Needle and syringe</description>
          </group>
        </group_list>
        <measure>
          <title>Diameter of Skin Bleb</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No wheal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wheal &gt; 0 mm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.130</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Fluid Leakage on Skin at Injection Site</title>
        <time_frame>Immediately post-vaccination</time_frame>
        <population>For adults, the skin fluid deposition was estimated and categorized by the vaccinator (e.g., no wetness, damp skin, flow on skin, spray in air); for infants, volume was measured objectively and categorized by the filter paper technique (units in µl).</population>
        <group_list>
          <group group_id="O1">
            <title>INFANTS: Bioject Intradermal (ID) Pen</title>
            <description>Intradermal administration of BCG vaccine via the Bioject ID Pen.
Bioject ID Pen</description>
          </group>
          <group group_id="O2">
            <title>INFANTS: Needle and Syringe</title>
            <description>Intradermal administration of BCG vaccine via needle and syringe.
Needle and syringe</description>
          </group>
          <group group_id="O3">
            <title>ADULTS: Bioject Intradermal (ID) Pen</title>
            <description>Intradermal administration of BCG vaccine via the Bioject ID Pen.
Bioject ID Pen</description>
          </group>
          <group group_id="O4">
            <title>ADULTS: Needle and Syringe</title>
            <description>Intradermal administration of BCG vaccine via needle and syringe.
Needle and syringe</description>
          </group>
        </group_list>
        <measure>
          <title>Fluid Leakage on Skin at Injection Site</title>
          <population>For adults, the skin fluid deposition was estimated and categorized by the vaccinator (e.g., no wetness, damp skin, flow on skin, spray in air); for infants, volume was measured objectively and categorized by the filter paper technique (units in µl).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>≤ 2.5 µl</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 2.5 µl to ≤ 5 µl</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 5 µl to ≤ 10 µl</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 10 µl to ≤ 20 µl</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 20 µl</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No wetness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Damp skin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flow on skin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spray in air</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>14 weeks for infants, 12 weeks for adults</time_frame>
      <desc>Infants attended study visits 4, 10, and 14 weeks after vaccination, and parents were contacted by telephone 1, 7, and 14 days after vaccination. Adults were seen 1, 2, 4, and 12 weeks after vaccination.</desc>
      <group_list>
        <group group_id="E1">
          <title>INFANTS: Bioject Intradermal (ID) Pen</title>
          <description>Intradermal administration of BCG vaccine via the Bioject ID Pen.
Bioject ID Pen</description>
        </group>
        <group group_id="E2">
          <title>INFANTS: Needle and Syringe</title>
          <description>Intradermal administration of BCG vaccine via needle and syringe.
Needle and syringe</description>
        </group>
        <group group_id="E3">
          <title>ADULTS: Bioject Intradermal (ID) Pen</title>
          <description>Intradermal administration of BCG vaccine via the Bioject ID Pen.
Bioject ID Pen</description>
        </group>
        <group group_id="E4">
          <title>ADULTS: Needle and Syringe</title>
          <description>Intradermal administration of BCG vaccine via needle and syringe.
Needle and syringe</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Neonatal jaundice</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Viral pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="15"/>
                <counts group_id="E4" events="10" subjects_affected="10" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Drinking less than usual</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Neck muscle spasms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="33"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="33"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Coryza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Scar</sub_title>
                <counts group_id="E1" events="24" subjects_affected="24" subjects_at_risk="33"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="33"/>
                <counts group_id="E3" events="15" subjects_affected="15" subjects_at_risk="15"/>
                <counts group_id="E4" events="13" subjects_affected="13" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="30" subjects_affected="30" subjects_at_risk="33"/>
                <counts group_id="E2" events="24" subjects_affected="24" subjects_at_risk="33"/>
                <counts group_id="E3" events="14" subjects_affected="14" subjects_at_risk="15"/>
                <counts group_id="E4" events="17" subjects_affected="15" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Ulceration</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="33"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="33"/>
                <counts group_id="E3" events="15" subjects_affected="15" subjects_at_risk="15"/>
                <counts group_id="E4" events="15" subjects_affected="15" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Scaling</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="33"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="33"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="15"/>
                <counts group_id="E4" events="11" subjects_affected="11" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Pustule</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="33"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="33"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="15"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Papule</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="33"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="33"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Scab</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="33"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="33"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" events="30" subjects_affected="30" subjects_at_risk="33"/>
                <counts group_id="E2" events="27" subjects_affected="27" subjects_at_risk="33"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Diaper rash</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Tenderness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E3" events="16" subjects_affected="15" subjects_at_risk="15"/>
                <counts group_id="E4" events="17" subjects_affected="15" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Induration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E3" events="15" subjects_affected="15" subjects_at_risk="15"/>
                <counts group_id="E4" events="17" subjects_affected="15" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Drainage</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="33"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="33"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="15"/>
                <counts group_id="E4" events="14" subjects_affected="14" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Pigmentation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Itching</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Oral herpes zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Courtney Jarrahian</name_or_title>
      <organization>PATH</organization>
      <phone>206-285-3500</phone>
      <email>cjarrahian@path.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

